These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

357 related articles for article (PubMed ID: 25034573)

  • 1. Reproductive function assessment after surgery plus chemotherapy for germ cell ovarian tumors (MOGCT): novel clues deriving from the field of fertility preservation.
    Ottolina J; Mangili G; Sigismondi C; Vanni VS; Viganò P; Candiani M
    Gynecol Endocrinol; 2014 Nov; 30(11):778-80. PubMed ID: 25034573
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term oncological and reproductive outcomes of fertility-sparing cytoreductive surgery in females aged 25 years and younger with malignant ovarian germ cell tumors.
    Ertas IE; Taskin S; Goklu R; Bilgin M; Goc G; Yildirim Y; Ortac F
    J Obstet Gynaecol Res; 2014 Mar; 40(3):797-805. PubMed ID: 24320102
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Menstrual function and childbearing potential after fertility-sparing surgery and platinum-based chemotherapy for malignant ovarian germ cell tumours.
    Gadducci A; Lanfredini N; Tana R
    Gynecol Endocrinol; 2014 Jul; 30(7):467-71. PubMed ID: 24702194
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fertility and gonadal function after adjuvant therapy in women diagnosed with a malignant ovarian germ cell tumor (MOGCT) during the "cisplatin era".
    Solheim O; Tropé CG; Rokkones E; Kærn J; Paulsen T; Salvesen HB; Hagen B; Vereide AB; Fosså SD
    Gynecol Oncol; 2015 Feb; 136(2):224-9. PubMed ID: 25511159
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Young girls with malignant ovarian germ cell tumors can undergo normal menarche and menstruation after fertility-preserving surgery and adjuvant chemotherapy.
    Yoo SC; Kim WY; Yoon JH; Chang SJ; Chang KH; Ryu HS
    Acta Obstet Gynecol Scand; 2010; 89(1):126-30. PubMed ID: 19878051
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-Müllerian hormone as a marker of ovarian reserve in patients with ovarian malignancies who have undergone fertility-preserving surgery and chemotherapy.
    Iwase A; Sugita A; Hirokawa W; Goto M; Nakahara T; Bayasula ; Kajiyama H; Shibata K; Nagatomo Y; Kikkawa F
    Gynecol Endocrinol; 2013 Apr; 29(4):357-60. PubMed ID: 23305483
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcomes of pediatric and adolescent girls with malignant ovarian germ cell tumors.
    Park JY; Kim DY; Suh DS; Kim JH; Kim YM; Kim YT; Nam JH
    Gynecol Oncol; 2015 Jun; 137(3):418-22. PubMed ID: 25842162
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A retrospective study of reproductive outcomes after fertility-sparing surgery and postoperative adjuvant chemotherapy in malignant ovarian germ cell tumors and sex cord-stromal tumors.
    Zhang N; Chen R; Hua K; Zhang Y
    J Ovarian Res; 2017 Jul; 10(1):52. PubMed ID: 28750644
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fertility sparing surgery in malignant ovarian Germ cell tumor (MOGCT): 15 years experiences.
    Zamani N; Rezaei Poor M; Ghasemian Dizajmehr S; Alizadeh S; Modares Gilani M
    BMC Womens Health; 2021 Aug; 21(1):282. PubMed ID: 34348686
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Conservative surgery to preserve ovarian function in patients with malignant ovarian germ cell tumors. A review of 74 cases.
    Low JJ; Perrin LC; Crandon AJ; Hacker NF
    Cancer; 2000 Jul; 89(2):391-8. PubMed ID: 10918171
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gonadotrophin-releasing hormone agonists for fertility preservation: unraveling the enigma?
    Hasky N; Uri-Belapolsky S; Goldberg K; Miller I; Grossman H; Stemmer SM; Ben-Aharon I; Shalgi R
    Hum Reprod; 2015 May; 30(5):1089-101. PubMed ID: 25796551
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Survival and reproductive outcomes in women treated for malignant ovarian germ cell tumors.
    Weinberg LE; Lurain JR; Singh DK; Schink JC
    Gynecol Oncol; 2011 May; 121(2):285-9. PubMed ID: 21256579
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Prognostic factors analysis in patients with ovarian malignant germ cell tumor treated with fertility-preserving surgery].
    Yang ZJ; Wei RJ; Li L
    Zhonghua Fu Chan Ke Za Zhi; 2012 Dec; 47(12):898-904. PubMed ID: 23324188
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neo-adjuvant chemotherapy in the treatment of advanced malignant germ cell tumors of ovary.
    Talukdar S; Kumar S; Bhatla N; Mathur S; Thulkar S; Kumar L
    Gynecol Oncol; 2014 Jan; 132(1):28-32. PubMed ID: 24145115
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Results of fertility preserving operations in malignant ovarian tumors].
    Kleine W
    Zentralbl Gynakol; 1996; 118(6):317-21. PubMed ID: 8768006
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fertility-sparing surgery for patients with malignant ovarian germ cell tumors: 10 years of clinical experience from a tertiary referral center.
    Mikuš M; Benco N; Matak L; Planinić P; Ćorić M; Lovrić H; Radošević V; Puževski T; Bajt M; Vujić G
    Arch Gynecol Obstet; 2020 May; 301(5):1227-1233. PubMed ID: 32253553
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An Analysis of Prognostic Factors in Patients with Ovarian Malignant Germ Cell Tumors Who Are Treated with Fertility-Preserving Surgery.
    Yang ZJ; Liu ZC; Wei RJ; Li L
    Gynecol Obstet Invest; 2016; 81(1):1-9. PubMed ID: 25967958
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reproductive outcomes following fertility-sparing surgery for malignant ovarian germ cell tumors: A systematic review of the literature.
    Morrison A; Nasioudis D
    Gynecol Oncol; 2020 Aug; 158(2):476-483. PubMed ID: 32513565
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Does the time interval between antimüllerian hormone serum sampling and initiation of ovarian stimulation affect its predictive ability in in vitro fertilization-intracytoplasmic sperm injection cycles with a gonadotropin-releasing hormone antagonist? A retrospective single-center study.
    Polyzos NP; Nelson SM; Stoop D; Nwoye M; Humaidan P; Anckaert E; Devroey P; Tournaye H
    Fertil Steril; 2013 Aug; 100(2):438-44. PubMed ID: 23602319
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of ABVD chemotherapy on ovarian reserve after fertility preservation in reproductive-aged women with Hodgkin lymphoma.
    Policiano C; Subirá J; Aguilar A; Monzó S; Iniesta I; Rubio Rubio JM
    J Assist Reprod Genet; 2020 Jul; 37(7):1755-1761. PubMed ID: 32488563
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.